

29 August 2022

UMW (UMWH MK)

Racing Towards a Strong FY22

- Stay NEUTRAL, with new MYR3.10 TP from MYR2.90, 1% upside. 1H22
 earnings beat our and Street estimates, mainly due to stronger-thanexpected margins, as UMW's cost containment measures have cushioned
 the impact of a strengthening USD/MYR and costlier car parts. In light of
 the strong YTD UMW Toyota (UMWT) sales, management raised UMWT's
 target to 80k from 73k, and we lift our FY22F to 88k from 85k, given the
 easing supply chain issues. Still, softening FY23F sales are of concern.
- Results beat. 2Q22 profit of MYR102m brought 1H22 profit to MYR211m, exceeding expectations at 65% and 61% of our and Street full year estimates. The deviation is mainly due to stronger-than-expected margins, as revenue was in line. No dividends declared, as expected.
- Results highlights. QoQ, 2Q22 PBT grew 6% mainly driven by the recovery of its Equipment and Manufacturing & Engineering segments, which both saw margin recovery. Automotive revenue grew 1.5% but PBT slipped 1.4% as margin eased slightly, which we attribute to costlier car parts and a stronger USD/MYR during 2Q22. Despite that, a higher effective tax rate weighted and core profit fell 6% QoQ, all segments recovered strongly against a locked-down 2Q21.
- Orders are gradually recovering MoM, as August orders rose from July, when Perodua and UMWT orders fell by 20-30% from 1H22 average. Currently, UMWT has c.50k backlog orders, and Perodua c.250k. In July, Perodua had 24k new orders, with the Alza alone contributing 9k. Despite striking a cautious tone on 2023 due to macroeconomic headwinds, management thinks that UMW could benefit from downtrading, given the group's affordable options of Toyota Vios & Yaris, and all Perodua models.
- Supply chain issues are easing, as UMWT is currently running at close to 100% capacity, thanks to its alternative sources for parts. Perodua's vendors, on the other hand, are still facing foreign labour shortages.
- Sales target. UMWT raised its 2022 sales target to 80k units, from 73k. YTD-July, UMWT has sold 52.5k units, and aims to deliver 8k units each month for the remainder of 2022, which we think could help it achieve close to 90k units. Thus, we lift our UMWT target to 88k from 85k. We also lift Perodua's FY23-FY24 targets to 210k-220k from 200k-210k in light of the strong demand for the all-New Perodua Alza.
- Forecasts. We lift FY22F earnings by 27% on higher auto margin assumptions and stronger UMWT sales, as well as FY23F-FY24F earnings by 6-3% on higher Perodua sales. Higher FY23F earnings lift our TP to MYR3.10, from MYR2.90, based on an unchanged 12x FY23F P/E. Our TP includes a 2% ESG discount. Despite the strong results and an anticipated strong FY22, we remain cautious on the softening UMWT and Perodua sales in FY23F, especially given Perodua's disproportionate vulnerability to macroeconomic headwinds.
- Key risks: Weaker-than-expected orders and deliveries, softer-than-expected margins, and stronger-than-expected USD/MYR. The converse represents the key upside risks.

Forecasts and Valuation	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Total turnover (MYRm)	9,555	11,061	14,457	12,027	12,362
Recurring net profit (MYRm)	285	259	415	306	323
Recurring net profit growth (%)	11.7	(9.1)	60.0	(26.2)	5.5
Recurring P/E (x)	12.55	13.80	8.62	11.69	11.08
P/B (x)	0.9	0.9	0.8	0.7	0.7
P/CF (x)	3.78	13.66	14.15	6.82	9.32
Dividend Yield (%)	1.3	1.9	1.9	1.9	1.9
EV/EBITDA (x)	4.98	14.12	2.63	3.20	2.96
Return on average equity (%)	7.3	(4.4)	9.5	6.4	6.2
Net debt to equity (%)	7.6	net cash	net cash	net cash	net cash

Source: Company data, RHB

Malaysia Results Review

Consumer Cyclical | Auto & Autoparts

Neutral (Maintained)

Target Price (Return): MYR3.10 (+1%)
Price (Market Cap): MYR3.06 (USD800m)
ESG score: 2.90 (out of 4)
Avg Daily Turnover (MYR/USD) 0.54m/0.12m


Analyst

Jim Lim Khai Xhiang +603 9280 8683 jim.lim@rhbgroup.com



Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	3.0	8.1	(8.4)	(1.3)	(4.4)
Relative	7.3	5.6	(5.7)	4.5	1.0
52-wk Price low	/high (MYR)			2.83	- 3.48



Source: Bloomberg

Overall ESG Score: 2.90 (out of 4)

E: GOOD

UMW has taken efforts to monitor and improve its environmental standing, especially with energy consumption, carbon emissions, and water management. Its carbon footprint increased 2.36% in FY19.

S: GOOD

Aside from the up-to-date health & safety policies and guidelines, UMW is also consistent in its CSR participation – achieving 9,241 volunteer hours in 2019. It recorded average training hours of 12.36 hours per employee in FY19.

G: GOOD

Management has held regular engagements with the market and media while adhering to Global Reporting Initiative Sustainability Reporting standards and principles.

Note

Small cap stocks are defined as companies with a market capitalisation of less than USD0.5bn.



Financial Exhibits

Asia Malaysia Consumer Cyclical UMW UMWH MK

Valuation basis

Neutral

12x P/E on forward earnings

Key drivers

- i. Introduction of attractive new car models;
- ii. Turnaround at various legacy non-core oil and
- gas businesses; iii. Long term growth potential from aerospace business.

Key risks

- Weaker-than-expected orders and deliveries;
- ii. Softer-than-expected margins;iii. Stronger-than-expected USD/MYR.

Company Profile

UMW is the largest company in the automotive sector. Its 51%-owned subsidiary UMW-Toyota imports, assembles and distributes Toyota and Lexus vehicles in Malaysia.

Financial summary (MYR)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Recurring EPS	0.24	0.22	0.35	0.26	0.28
DPS	0.04	0.06	0.06	0.06	0.06
BVPS	3.31	3.52	3.94	4.26	4.60
Return on average equity (%)	7.3	(4.4)	9.5	6.4	6.2

Valuation metrics	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Recurring P/E (x)	12.55	13.80	8.62	11.69	11.08
P/B (x)	0.9	0.9	0.8	0.7	0.7
FCF Yield (%)	20.3	(4.0)	(4.1)	3.5	(0.5)
Dividend Yield (%)	1.3	1.9	1.9	1.9	1.9
EV/EBITDA (x)	4.98	14.12	2.63	3.20	2.96
EV/EBIT (x)	12.20	na	4.16	5.46	5.05

Income statement (MYRm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Total turnover	9,555	11,061	14,457	12,027	12,362
Gross profit	1,500	1,194	2,615	2,068	2,140
EBITDA	632	172	906	669	687
Depreciation and amortisation	(374)	(344)	(333)	(277)	(284)
Operating profit	258	(171)	574	393	403
Net interest	(116)	(108)	(124)	(107)	(103)
Pre-tax profit	401	37	886	604	631
Taxation	(78)	33	(204)	(82)	(85)
Reported net profit	274	(177)	415	306	323
Recurring net profit	285	259	415	306	323

Cash flow (MYRm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Change in working capital	460	(221)	(188)	134	(18)
Cash flow from operations	946	262	253	524	384
Capex	(221)	(406)	(400)	(400)	(400)
Cash flow from investing activities	(110)	12	(12)	(138)	(125)
Dividends paid	(23)	(68)	(68)	(68)	(68)
Cash flow from financing activities	(602)	(275)	(296)	(244)	(251)
Cash at beginning of period	1,472	2,051	2,941	2,886	3,029
Net change in cash	234	(2)	(55)	143	8
Ending balance cash	1,703	2,057	2,886	3,029	3,037

Balance sheet (MYRm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Total cash and equivalents	2,051	2,941	2,886	3,029	3,037
Tangible fixed assets	2,463	2,531	2,569	2,613	2,651
Total investments	2,370	2,537	2,537	2,537	2,537
Total assets	11,447	12,173	13,262	12,890	13,102
Short-term debt	548	655	555	455	355
Total long-term debt	1,990	2,133	2,133	2,133	2,133
Total liabilities	5,030	5,410	6,211	5,607	5,577
Total equity	6,417	6,763	7,051	7,283	7,525
Total liabilities & equity	11,447	12,173	13,262	12,890	13,102

Key metrics	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Revenue growth (%)	(18.6)	15.8	30.7	(16.8)	2.8
Recurrent EPS growth (%)	11.7	(9.1)	60.0	(26.2)	5.5
Gross margin (%)	15.7	10.8	18.1	17.2	17.3
Operating EBITDA margin (%)	6.6	1.6	6.3	5.6	5.6
Net profit margin (%)	2.9	(1.6)	2.9	2.5	2.6
Dividend payout ratio (%)	17.0	(38.2)	16.3	22.1	21.0
Capex/sales (%)	2.3	3.7	2.8	3.3	3.2
Interest cover (x)	2.23	(1.58)	4.63	3.65	3.90

Source: Company data, RHB



29 August 2022

Perodua currently has an order backlog of c.250k, and it expects to deliver most of the sales and service tax-exempt orders before end-Mar 2023. At the moment, different Perodua models have varying wait times: 1-2 months for the Ativa and Aruz; 4-5 months for the Axia, 5-6 months for the Myvi; 7-8 months for the Bezza. The all new Alza has the longest wait time – potentially up to a year, per our estimates, as there are currently more than 41,000 orders for it, with a current Alza production capacity of 3.5k a month. However, Perodua is looking to shift more production towards the Alza to cater to the strong demand.

Perodua's first hybrid electric vehicle (HEV) potentially in 2024. Currently, Perodua is studying the development of a hybrid model, with production potentially in 2024. MBM Resources' (MBM MK; NEUTRAL, TP: MYR3.00) management believes that with the current high cost of EV batteries, a fully-battery electric Perodua would be too expensive for Perodua's target customers. Thus, Perodua will slowly electrify its models by first exploring the more affordable hybrid options.

Equipment, mechanical & engineering, and aerospace segments all saw QoQ and YoY improvements following the broad reopening of the economy, which also led to margin recovery. Notably, the auto components and lubricants all saw higher demand in 1H22 given the strong demand for vehicles. Though the aerospace segment is still lagging behind as a result of low delivery of fan cases, it is expected to recover along with the resumption in air travel.

Results At a Glance

Figure 1: Earnings review

FYE Dec	2Q21	1Q22	2Q22	QoQ	YoY	1H21	1H22	YoY	Comments
(MYRm)	20,21	IQZZ	ZQZZ	(%)	(%)	11121	11122	(%)	Comments
Revenue	2,445	3,651	3,731	2	53	5,399	7,382	37	2Q22 revenue rose QoQ mainly driven by the automotive segment, on higher car sales
EBIT	21	146	141	(3)	582	110	287	159	3 · · · · · · · · · · · · · · · · · · ·
Finance costs	(26)	(39)	(25)	(35)	(1)	(53)	(64)	21	
Investment income	12	13	17	30	36	25	30	18	
Associates	25	97	98	1	288	113	194	72	
Pretax Profit	33	216	230	6	606	195	446	129	2Q22 PBT rose 6% QoQ mainly driven by margin recovery at the equipment and manufacturing & engineering segments from cost saving initiatives, outweighing the decline in automotive margin
Tax	(11)	(43)	(57)	30	411	(50)	(100)	98	5
MI	(8)	(54)	(49)	(10)	528	(34)	(103)	204	
Core Net Profit	(20)	109	102	(6)	(602)	77	211	175	2Q22 core profit slipped 6% QoQ mainly due to higher effective tax rate. 1H22 core profit of MYR211m exceeded our and Street estimates
EBIT margin (%)	0.8	4.0	3.8			2.0	3.9		
Pretax margin (%)	1.3	5.9	6.2			3.6	6.0		
Eff tax rate (%)	(34.0)	(20.1)	(24.6)			(25.8)	(22.4)		
Net Margin (%)	(0.8)	3.0	2.7			1.4	2.9		

Source: Company data, RHB



Figure 2: Earnings review - segmental breakdown

FYE Dec	2Q21	1Q22	2Q22	QoQ	YoY	1H21	1H22	YoY	Comments
(MYRm)				(%)	(%)			(%)	
Automotive	1,982	3,070	3,117	2	57	4,378	6,188	41	QoQ, revenue was higher due to higher car sales and sale of parts
Equipment	300	372	367	(1)	22	632	738	17	QoQ, revenue was marginally lower due to the lower contribution from the industrial equipment sub-segment QoQ, revenue was marginally lower due to lower contribution from the aerospace sub- segment, following the lower delivery of fan
Manufacturing & engineering	160	227	226	(0)	42	390	454	16	cases
Criginoching									YTD, YoY, revenue rose most notably from the auto-components and lubricants sub- segments
Others	3	(18)	20	(212)	510	(1)	2	(294)	· ·
Revenue	2,445	3,651	3,731	2	53	5,399	7,382	37	
Automotive	35	206	203	(1)	486	180	409	127	Despite the higher revenue, PBT softened QoQ due to lower margins, which we attribute to costlier car parts and a stronger USD/MYR
Equipment	32	32	35	12	11	54	67	25	Increased QoQ due to margin recovery from various cost saving initiatives
Manufacturing & engineering	(6)	11	13	23	(315)	2	24	922	Increased QoQ due to margin recovery from various cost saving initiatives
Others	(28)	(32)	(21)	33	23	(41)	(53)	30	· ·
PBT	33	216	230	6	606	195	446	129	
PBT Margins									
Automotive	1.7	6.7	6.5			4.1	6.6		
Equipment	10.6	8.5	9.7			8.5	9.1		
Manufacturing & engineering	(3.8)	4.7	5.8			0.6	5.2		

Source: Company data, RHB

Figure 3: UMW's vehicle sales summary

FYE Dec	2Q21	1Q22	2Q22	QoQ	YoY	1H21	1H22	YoY	Comments
(units)				(%)	(%)	YTD	YTD	(%)	
									QoQ growth as there was a rush to deliver
Toyota	16,960	22,447	23,463	4.5	38.3	34,111	45,910	34.6	orders in June
·oyolu	10,000	,	20,100	0	00.0	0.,	10,010	00	YoY recovery as 1H22 saw COVID-19 related lockdowns
- Passenger	13,038	14,631	17,019	16.3	30.5	23,638	31,650	33.9	
- Commercial	3,922	7,816	6,444	(17.6)	64.3	10,473	14,260	36.2	
Perodua	39,381	61,624	65,719	6.6	66.9	97,290	127,343	30.9	QoQ growth as there was a rush to deliver orders in June, and as 1Q22 saw some supply chain disruptions due to Dec 2021 flash floods YoY recovery as 1H22 saw COVID-19 related
Passangar	39,381	61,624	65,719	6.6	66.9	97,290	127,343	30.9	lockdowns
- Passenger	•	,		0.0	00.9	,		30.9	
- Commercial	0	0	0			0	0		
Total	56,341	84,071	89,182	6.1	58.3	131,401	173,253	31.9	

Source: Company data, RHB

Figure 4: Key assumptions

FYE Dec	Dec-19	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Toyota/Lexus TIV (units) – current	70,009	59,320	72,394	88,000	70,000	72,000
Toyota/Lexus TIV (units) – previous				85,000		
Perodua TIV (units) – current	240,341	220,154	190,291	250,000	210,000	220,000
Perodua TIV (units) – previous					200,000	210,000

Source: Company data, RHB



Recommendation Chart




Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2022-07-15	Neutral	2.90	2.83
2022-05-25	Neutral	3.64	3.35
2022-03-15	Neutral	3.29	3.06
2022-02-28	Neutral	3.29	3.07
2021-11-30	Neutral	2.83	3.08
2021-08-27	Neutral	2.94	3.11
2021-07-27	Neutral	2.94	2.91
2021-05-25	Neutral	3.43	3.25
2021-04-22	Neutral	3.40	3.38
2021-02-26	Neutral	2.98	2.99
2020-11-26	Neutral	2.65	2.78
2020-08-28	Neutral	2.40	2.60
2020-06-08	Neutral	2.65	2.89
2020-03-27	Neutral	2.40	2.34
2020-02-28	Sell	2.90	3.16

Source: RHB, Bloomberg

ESG Rating History



RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next

12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels Sell: Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a



member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Save as disclosed in the following link RHB Research conflict disclosures – Aug 2022 and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
 RHBIB is not a market maker in the securities or capital market products of the
- subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report *For the avoidance of doubt, the confirmation is only limited to the staff of research
- RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

- Save as disclosed in the following link RHB Research conflict disclosures Aug 2022 and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:
 RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
 RHB Securities (Thailand) PCL is not a market maker in the securities or capital
- market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
- *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesia

Save as disclosed in the following link RHB Research conflict disclosures – Aug 2022 and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report. For the avoidance of doubt, interest in securities include the following:
 - a) Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the
 - subject company's securities covered in this report*;
 Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*
 - Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.
- Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.

 None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a
- director or board member* of the subject company(ies) covered in this report. PT RHB Sekuritas Indonesia did not receive compensation for investment banking
- or corporate finance services from the subject company in the past 12 months.
- PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

Notes:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

*The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Singapore

Save as disclosed in the following link RHB Research conflict disclosures – Aug 2022 and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
- 3. RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- 5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research analysts do not receive any compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysts.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:



(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	=

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd

Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel: +603 9280 8888 Fax: +603 9200 2216

BANGKOK

RHB Securities (Thailand) PCL

10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand

Tel: +66 2088 9999 Fax:+66 2088 9799

JAKARTA

PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia

Tel: +6221 509 39 888 Fax: +6221 509 39 777

SINGAPORE

RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470